SSelectStock
Sign in

JBCHEPHARMJB Chemicals & Pharmaceuticals Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

2,408.90
0.00%
74Strong

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)39,940.60
P/E55.86
P/B9.60
PEG
ROE %18.69
ROCE %21.60
Debt / Equity0.00
EPS44.53
Revenue Growth %-4.80
Profit Growth %-31.00
Dividend Yield %1.16
Promoter Holding %49.23
FII Holding %30.81
DII Holding %
Beta-0.02

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG80%2,408.902,354.992,502.901.74
BUYConviction 78%

Why buy

  • ROE: 18.7%
  • ROCE: 21.6%
  • Debt/Equity: 0.00
  • RSI: 61
  • MACD: bullish
  • Price vs EMA21: above
  • Pullback to 21-EMA signal (setup quality 80%)

Bull case

  • ROE: 18.7%
  • ROCE: 21.6%
  • Debt/Equity: 0.00
  • RSI: 61

Bear case

  • Revenue growth: -4.8% YoY
  • Profit growth: -31.0% YoY
  • Volume: 0.0x 20-day average
  • Beta: -0.02

Key risks

  • Revenue growth: -4.8% YoY
  • Profit growth: -31.0% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹2,408.90
Stop Loss
₹2,274.12
risk 5.6%
Target 1 (1.5R)
₹2,611.07
+8.4%
Target 2 (3R)
₹2,813.24
+16.8%
Support (20d)
₹2,163.10
Resistance (52w)
₹2,525.50
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹134.78/share
ATR (volatility)
₹53.91
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹53.91). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
52
Technical
76
Momentum
92
Risk (safety)
83

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.39%
82
HESTERBIO 4.01%
81
LUPIN 1.45%
80
SUNPHARMA 1.14%
79
GRANULES 0.65%
79

About

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.